BioLife SolutionsBLFS -1.30%72 Return-on-Tangible-Asset is 2.49% as of Mar. 2026. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.64 (Fairly Valued). The stock has 5 warning signs investors should review. Among 857 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 54.73% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. BioLife Solutions's annualizedNet Income for the quarter that ended in Mar. 2026 was $4.74 Mil. BioLife Solutions's average total tangible assets for the quarter that ended in Mar. 2026 was $190.71 Mil. Therefore, BioLife Solutions's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 2.49%.
The historical rank and industry rank for BioLife Solutions's Return-on-Tangible-Asset or its related term are showing as below:
BLFS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -86.81 Med: -17.93 Max: 2.17
Current: -1.66
During the past 13 years, BioLife Solutions's highest Return-on-Tangible-Asset was 2.17%. The lowest was -86.81%. And the median was -17.93%.
BLFS's Return-on-Tangible-Asset is ranked worse than 54.73% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.57
vs BLFS: -1.66
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
BioLife Solutions Return-on-Tangible-Asset Related Terms
BioLife Solutions Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLFS vs STAA, ATRC, KMTS: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 2.49% mean?
BioLife Solutions (BLFS) has a Return-on-Tangible-Asset of 2.49% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioLife Solutions and its competitors. According to the industry distribution chart, BioLife Solutions ranks #469 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 54.7%.
Is BioLife Solutions' Return-on-Tangible-Asset too high?
BioLife Solutions' current Return-on-Tangible-Asset is 2.49%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.57. BioLife Solutions' value of 2.49% is 336.8% above this industry median. Based on the distribution chart, BioLife Solutions ranks #469 out of 857 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Return-on-Tangible-Asset compare to STAA and ATRC?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #469 out of 857 companies for Return-on-Tangible-Asset. This places BioLife Solutions in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.57. BioLife Solutions' value of 2.49% is 336.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.57, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Return-on-Tangible-Asset of 2.49% is 336.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Return-on-Tangible-Asset is 2.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.64, compared to a current price of $28.10 — trading 1.9% below its estimated fair value. The current Return-on-Tangible-Asset is 2.49% and 336.8% above the Medical Devices & Instruments industry median of 0.57. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Return-on-Tangible-Asset is 2.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be undervalued.
The current stock price of $28.10 is trading 1.9% below its estimated GF Value™ of $28.64.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
Return-on-Tangible-Asset: 2.49%
GF Value™: $28.64 vs. price of $28.10 (1.9% below fair value)
Industry Position: 336.8% above the Medical Devices & Instruments median (#469 of 857)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
